ReviewIranian journal of pharmaceutical research : IJPR2022
Donepezil Beyond Alzheimer's Disease? A Narrative Review of Therapeutic Potentials of Donepezil in Different Diseases.
Review in Iranian journal of pharmaceutical research : IJPR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Association of Cholinergic Stimulation with Improved Functional Performance and Neurotrophic Markers in Mild Cognitive Impairment.Molecular neurobiology · 2026Article
- Optimization and Metabolomic Profiling ofInternational journal of molecular sciences · 2026Article
- Medicinal Chemistry Perspectives on Drug Repurposing: Innovative Approaches and Therapeutic Breakthrough.Therapeutic innovation & regulatory science · 2026Review
- Evidence-Based Strategies for Addressing Cancer- and Treatment-Related Cognitive Impairment: A Review.Biomolecules & therapeutics · 2026Review
- Analysis of the Efficacy of Acetylcholinesterase Inhibitors in the Treatment of Alzheimer's Disease, Literature Review.International journal of molecular sciences · 2026Review
- Article
- Metabolic and neuroimmune control of rheumatoid arthritis: therapeutic implications of FXR and α7-nAChR axes.Inflammopharmacology · 2026Review
- Behçet Disease and Cognitive Impairment: A Case Study of an Overlooked Symptom.The American journal of case reports · 2025Article
- Clinical effect of donepezil hydrochloride in the treatment of Parkinson's disease patients: a meta-analysis.American journal of translational research · 2025Review
- Role of the Central Cholinergic Nervous System in Motor and Non-Motor Symptoms of Parkinson's Disease.Current neuropharmacology · 2025Review
- Efficacy of medications in controlling cognitive dysfunction in Alzheimer's : a systematic review.Dementia & neuropsychologia · 2025Review
- Paternal preconception donepezil exposure enhances learning in offspring.Behavioral and brain functions : BBF · 2024Article
- Muscarinic Receptors and Alzheimer's Disease: New Perspectives and Mechanisms.Current issues in molecular biology · 2024Review
- Neuroinflammation in Neurodegenerative Disorders: Current Knowledge and Therapeutic Implications.International journal of molecular sciences · 2024Review
- Nanoparticle-Based Drug Delivery Systems Enhance Treatment of Cognitive Defects.International journal of nanomedicine · 2024Review
- Effect of Butylphthalide soft capsules on cognitive function and dementia-related factors in elderly patients with Parkinson's disease dementia during the COVID-19 pandemic.American journal of translational research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Donepezil hydrochloride is an acetylcholine esterase inhibitor studied and approved to treat Alzheimer's disease (AD). However, this drug can have positive therapeutic potential in treating different conditions, including various neurodegenerative disorders such as other types of dementia, multiple sclerosis, Parkinson's disease, psychiatric and mood disorders, and even infectious diseases. Hence, this study reviewed the therapeutic potential of this drug in treating Alzheimer's and other diseases by reviewing the articles from databases including Web of Science, Scopus, PubMed, Cochrane, and Science Direct. It was shown that donepezil could affect the pathophysiology of these diseases via mechanisms such as increasing the concentration of acetylcholine, modulating local and systemic inflammatory processes, affecting acetylcholine receptors like nicotinic and muscarinic receptors, and activating various cellular signaling via receptors like sigma-1 receptors. Despite many therapeutic potentials, this drug has not yet been approved for treating non-Alzheimer's diseases, and more comprehensive studies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.